Overview
Rory Lootsma is an associate at the firm’s New York office. His practice focuses on patent prosecution.
Rory completed his undergraduate studies in Mechanical Engineering at Queen’s University and received his J.D. at the University of Toronto. While in law school, Rory chaired the Technology and Intellectual Property Group.
Rory joined the firm in 2021.
Education
- University of Toronto (J.D., 2021)
- Queen’s University (B.A.S.c Mechanical Engineering, 2017), First Class Honors, Queen’s University Medal in Mechanical Engineering
News & Insights
Articles
Medical Device Blog
- Zimmer Biomet to Acquire Paragon 28
- Edwards Lifesciences to Acquire Innovalve
- Middle District of North Carolina Grants Preliminary Injunction in Natera, Inc. v. Neogenomics Laboratories, Inc.
- Federal Circuit Vacates PTAB’s Decisions in Axonics, Inc. v. Medtronic, Inc.
- Federal Circuit Upholds Lower Court Decision in Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.
Latest Updates and News
Zimmer Biomet to Acquire Paragon 28
Zimmer Biomet recently announced entering a definitive agreement to acquire all outstanding common shares of Paragon 28. Under the agreement, Zimmer Biomet will pay $13.00 per share, valuing Paragon 28 at approximately $1.1 billion....
Edwards Lifesciences to Acquire Innovalve
Edwards Lifesciences recently announced that it would acquire Innovalve Bio Medical, an early-stage transcatheter mitral valve replacement (“TMVR”) company. Edwards had the option to acquire Innovalve following an initial investment in 2017. The acquisition is expected to close by the end of the year.
Middle District of North Carolina Grants Preliminary Injunction in Natera, Inc. v. Neogenomics Laboratories, Inc.
(December 27, 2023) Natera Inc. succeeded in obtaining a preliminary injunction against NeoGenomics Laboratories, Inc.’s medical assay test. Natera’s ongoing federal lawsuit alleges that NeoGenomics’ product “RaDaR,” a tumor informed molecular residual disease (“MRD”) assay, infringes two of Natera’s patents, U.S. Patent No. 11,519,035, entitled “Methods for Simultaneous Amplification of Target Loci,” and U.S. Patent No. 11,530,454, entitled “Detecting Mutations and Ploidy in Chromosomal Segments.”
Federal Circuit Vacates PTAB’s Decisions in Axonics, Inc. v. Medtronic, Inc.
Sacral neuromodulation stimulates nerves above the tailbone to treat fetal incontinence and related bowel and bladder control issues. After California-based Axonics Inc. (“Axonics”) entered the sacral neuromodulation market in late 2019, MedTronic sued for patent infringement. Axonics filed for inter partes review (IPR) of the asserted patents at the Patent Trial and Appeal Board (PTAB). Although MedTronic initially prevailed in the IPR, Axonics has now succeeded on appeal at the Federal Circuit.
Federal Circuit Upholds Lower Court Decision in Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.
The Federal Circuit has affirmed that Eagle Pharmaceuticals, Inc. did not infringe Par Pharmaceutical, Inc. patents, easing Eagle’s path to market a generic competitor to Par’s Vasostrict®